Immunohisto Chemical Expression of IDH1, ATRX and P53 in Low Grade Diffuse Gliomas at Armed Forces Institute of Pathology, Rawalpindi

Ayesha Arif; Farhan Akhtar; Ahmed Ahson; Hafeez Uddin; Rabia Ahmed; Aminah Ahmed

doi:10.51253/pafmj.v72i3.6851

Authors

Ayesha Arif Armed Forces Institute of Pathology/National University of Medical Science (NUMS) Rawalpindi Pakistan
Farhan Akhtar Army Medical College/National University of Medical Science (NUMS) Rawalpindi Pakistan
Ahmed Ahson Armed Forces Institute of Pathology/National University of Medical Science (NUMS) Rawalpindi Pakistan
Hafeez Uddin Armed Forces Institute of Pathology/National University of Medical Science (NUMS) Rawalpindi Pakistan
Rabia Ahmed Pakistan Naval Ship Shifa Hospital, Karachi Pakistan
Aminah Ahmed Rehman Medical College, Peshawar Pakistan

DOI:

https://doi.org/10.51253/pafmj.v72i3.6851

Keywords:

Diffuse glioma, IDH1, Low grade, p53, ATRX

Abstract

Objective: To determine the immune histochemical expression of IDH1, ATRX and p53 in low-grade diffuse gliomas.

Study Design: Cross-sectional study.

Place and Duration of Study: Department of Histopathology, Armed Forces Institute of Pathology, Rawalpindi Pakistan, from Jan to Jun 2020.

Methodology: Forty-two cases of low-grade diffuse glioma were included in the study. The cases were stratified into diffuse astrocytoma and oligodendroglioma based on results of immunohistochemistry expression for IDH1, ATRX and p53.

Results: The frontal lobe was the most commonly affected site 14 (33.3%). Based on the results of immunohistochemistry expression, 26 cases (61.9%) were diagnosed as an oligodendroglioma, while 16 cases (38.1%) were diagnosed as diffuse astrocytoma. All cases were assigned who grade II out of IV. In oligodendrogliomas, all cases (100%) were IDH1 mutants with the retained expression of ATRX and wild type expression of p53. Among the 16 cases of diffuse astrocytoma, IDH1 was mutant in 12 cases (75%), ATRX expression was lost in all cases, and p53 was mutant in 6 cases (37.5%).

Conclusion: The study showed that low-grade diffuse gliomas could be stratified and sub-classified in accordance with the World Health Organization (WHO) classification of CNS tumours (2016) successfully by application of immunohistochemistry for IDH1, ATRX and p53.